

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MARDUEL ALIX</u> (Last) (First) (Middle) <u>ONE EMBARACDERO CENTER, SUITE</u> <u>4050</u> (Street) <u>SAN FRANCISCO CA 94111</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/14/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC [CORT]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Series C Preferred Stock</u>	<u>(1)</u>	<u>(2)</u>	<u>Common Stock</u>	<u>1,698,274</u>	<u>(3)</u>	<u>I</u>	<u>see Remarks</u>

Explanation of Responses:

1. Immediately
2. Not applicable
3. Each Share is convertible without consideration into one (1) share of Common Stock.

Remarks:

Alix Marduel, Director, is a managing director ("md") of Alta BioPharma Management II, LLC ("ABMII") (which is the general partner of Alta BioPharma Partners II, L.P. ("ABPII")) and a manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBII"). She disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of her proportionate pecuniary interests therein. Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds, including ABPII and AEBII. The respective md and managers of ABPII and AEBII exercise sole voting and investment powers over the shares held by such funds. ABPII beneficially owns 1,632,012 shares of Series C Preferred Stock and AEBII beneficially owns 66,262 shares of Series C Preferred Stock. Jean Deleage, Alix Marduel and Farah Champsi (collectively known as the "principals") are managing directors of ABMII and managers of AEPII. As managing directors and managers, they may be deemed to share voting and investment powers over the shares held by the aforementioned funds. The principals disclaim beneficial ownership of the shares held by ABPII and AEBII except to the extent of their proportionate pecuniary interests therein.

/s/ Fred Kurland, CFO of
Corcept Therapeutics
Incorporated attorney-in-fact

04/14/2004

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY FOR SECTION 16 REPORTING

The undersigned hereby appoints Joseph K. Belanoff, in his capacity as Chief Executive Officer of Corcept Therapeutics Incorporated (the "Company"), Fred Kurland, in his capacity as Chief Financial Officer of the Company, and either of them with full power of substitution or their respective successors in any such offices, as the attorney-in-fact of the undersigned to execute and file with the Securities and Exchange Commission ("SEC") and any other authority required by the rules and regulations of the SEC or any market or exchange on which shares of the Company are traded and to submit to the Company, in the place and stead of the undersigned, SEC Forms 3, 4 and 5 and any successor reporting forms required by the SEC in connection with purchases and sales of securities of the Company and any other transactions in securities of the Company reportable on any such form. This Power of Attorney shall be effective until revoked by a written instrument executed by the undersigned and delivered to the Company at its headquarters to the attention of the Chief Financial Officer.

Dated: April 8, 2004

/s/ Alix Marduel

Name: Alix Marduel